Poster lunch (ID 46) Poster display session

64P - Identification of serum proteome signatures of male breast cancer (ID 311)

Presentation Number
64P
Lecture Time
12:15 - 12:15
Speakers
  • Eleni Zografos (Athens, Greece)
Session Name
Poster lunch (ID 46)
Location
Exhibition area, MARITIM Hotel Berlin, Berlin, Germany
Date
03.05.2019
Time
12:15 - 13:00

Abstract

Background

Male breast cancer (MBC) is a rare entity accounting for less than 1% of all malignancies in men. To date, little emphasis has been placed on the elucidation of serum protein alterations in male breast carcinogenesis, even though serum represents an attractive, non-invasive source for biomarker discovery.

Methods

In the present work, we employed two-dimensional gel electrophoresis (2-DE) separation and matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry analysis to detect differences in serum protein expression between MBC patients and healthy controls. The differential expression of selected proteins was confirmed by Western Blot analysis or Enzyme Linked Immunosorbent Assay (ELISA). Functional relationships analysis of the differentially expressed proteins was performed using the STRING v.10 database. The PANTHER database was used to reveal the molecular function and signaling pathway associated with each identified protein.

Results

A panel of differentially expressed serum proteins has been identified in MBC patients compared to controls, including proteins involved in the regulation of the cell cycle (ANCHR, CDC7, PDIP2), in mitochondrial function (ALDH2, TFB1M, NDUAB), in lipid metabolism and transport (APOA1, APOA4, APOE, APOH), in apoptosis and immune response (CD5L, CLUS, CCL14, LFTY2), in transcription (SSX3, STAT3, ZN223, ZN266, ZN273, ZN624, ZKSC7, RNZ2), in invasion and metastasis (FETUA, K1C10, K1C9, VTNC, AX2R, RAB37), in estrogen synthesis (CYP19A1) and with other diverse biological roles (BCAT1, CRYAB, CERU, ERMP1, MLH3, PRP18, RET4, SAMP, SYT1). Concurrently, several proteins were detected only in the MBC group (ARPC4, MP2K4, ENC1, MMP27).

Conclusions

These findings provide new insight into the distinct clinicopathological features of MBC and indicate that select serum proteomic biomarkers might help improve MBC management.

Legal entity responsible for the study

Department of Basic Medical Sciences, Laboratory of Biology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Funding

Has not received any funding.

Disclosure

F. Zagouri: Research and advisory grants: Novartis, Lilly, Pfizer. All other authors have declared no conflicts of interest.

Collapse